Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US

  • Based on a thorough reassessment Sesen Bio Inc SESN has decided to voluntarily pause further development in the U.S. of its lead asset, Vicineum, for non-muscle invasive bladder cancer (NMIBC).
  • The decision was based on a reassessment of the incremental development timeline and associated costs for an additional Phase 3 clinical trial following recent discussions with the FDA.
  • This decision enables Sesen Bio to conserve cash while assessing potential strategic alternatives. Additionally, the company intends to seek a partner to develop Vicineum further.
  • Related: Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer.
  • As of June 30, the company had $161.2 million in cash and cash equivalents.
  • Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
  • Price Action: SESN shares are down 17.8% at $0.74 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!